eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2020
vol. 7
 
Share:
Send email
Share:
abstract:
Guidelines/recommendations

Biological therapy of asthma – position statement of Polish Allergology Society (PTA) and Polish Society of Lung Diseases (PTChP)

Barbara Rogala
1
,
Maciej Kupczyk
2
,
Grażyna Bochenek
3
,
Paweł Śliwiński
4
,
Marcin Moniuszko
5
,
Joanna Glück
1
,
Rafał Dobek
4
,
Marek Kulus
6

  1. Katedra i Klinika Chorób Wewnętrznych, Alergologii i Immunologii Klinicznej, Śląski Uniwersytet Medyczny w Katowicach, Polska
  2. Klinika Chorób Wewnętrznych, Astmy i Alergii, Uniwersytet Medyczny w Łodzi, Polska
  3. II Katedra Chorób Wewnętrznych im. prof. A. Szczeklika, Uniwersytet Jagielloński Collegium Medicum w Krakowie, Polska
  4. II Klinika Chorób Płuc, Instytut Gruźlicy i Chorób Płuc w Warszawie, Polska
  5. Klinika Alergologii i Chorób Wewnętrznych, Uniwersytet Medyczny w Białymstoku, Polska
  6. Klinika Pneumonologii i Alergologii Wieku Dziecięcego, Warszawski Uniwersytet Medyczny, Polska
Alergologia Polska – Polish Journal of Allergology 2020; 7, 2: 64–80
DOI: https://doi.org/10.5114/pja.2020.96664
Online publish date: 2020/06/24
View full text Get citation
 
PlumX metrics:
Biological therapy is the breakthrough in the management of spectrum of various diseases. It also concerns asthma therapy. The data regarding the role of biologics in the treatment strategy of severe asthma are presented. The overview on how mediators of type 2 inflammation drives the pathology of the disease is given. It justifies the biological treatment options approved. The development of treatment strategy targeting non-type 2 inflammation is also highlighted. The data regarding the risk and safety of biologics are discussed. Document includes the featured rules of the classification of patients with severe asthma to this reliable and efficient therapy. The outlook how to perceive the safety of biologics in the time of COVID-19 epidemic is also given.
keywords:

severe asthma, immunopathology, biologics, efficacy, safety


Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.